Kinetics of Anti-Nucleocapsid IgG Response in COVID-19 Immunocompetent Convalescent Patients

International audienceAbstract The comprehension of a long-term humoral immune response against SARS-CoV-2 can shed light on the treatment and vaccination strategies of COVID-19 disease, improving the knowledge about this virus infection and/or re-infection. We assessed the IgG antibodies against SARS-CoV-2 nucleocapsid (N) protein (anti-SARS-CoV-2 (N) IgG) in 1441 COVID-19 convalescent patients within 15~months longitudinal study from middle-developed country. The main inclusion criteria was positive RT\textendash PCR result on nasopharyngeal swab samples at least one month before antibody testing and absence of any induced or inherited immunodeficiency. 92.7% of convalescent patients' serum contained anti-SARS-CoV-2 (N) IgG and only 1.3% of patients had a delayed antibody response. In the majority of convalescent patients' the durability of antibodies lasted more than one year. The kinetics of anti-SARS-CoV-2 (N) IgG took a bell-shaped character\textemdash increased first 25\textendash 30~weeks, then started to decrease, but were still detectable for more than 15~months. We found that on the one hand anti-SARS-CoV-2 humoral response level correlates with disease severity, on the other, in particular, the level of peak antibodies correlates with age\textemdash older patients develop more robust humoral response regardless of sex, disease severity and BMI